FERTI.NET HIGHLIGHTS
Special ESHRE 2000 Edition
Ferti.Net Highlights Archive

This year the 16th Annual Meeting of the European Society of Human Reproduction and Embryology took place from 25th to 28th June in Bologna, Italy. Leading experts from around the world presented new data on human reproduction and infertility treatment that are of interest not only for scientists and doctors but also for the general public.

Once again, Ferti.Net reporters covered the congress onsite in Bologna and reports were uploaded daily to the website . Listed below are the reports. Please visit Ferti.Net website for all our reports.

To view ESHRE congress photos, please click here

 

---

Monday, June 26

• A randomised controlled trial of progesterone supplementation during early gestation after IVF
  by A.N. Andersen (Denmark)

• Molecular genetics of follitropin and its receptors: from signalling to animal models
  by Sairam MR et al.
  Molecular Reproduction Research Laboratory, Clinical Research Institute of Montreal, Québec, Canada

• Spermatogonial stem cell preservation and transplantation
  by Schlatt S et al.
  Institute of Reproductive Medicine, University of Münster, Germany

• Artificial reproductive technology treatment and quality of life: physical and emotional distress
  by Kopitzke EJ and Wilson JF
  College of Medicine and Department of Behavioral Sciences, University of Kentucky, Lexington, Kentucky, USA

• Controlled ovarian stimulation for IVF cycles using the LHRH antagonist Cetrorelix (Cetrotide®): experience from one centre after changing the routine protocol from the long antagonist to the multiple dose antagonist protocol
  by Ludwig M et al.
  Department of Gynaecology and Obstetrics and Department of Social Medicine, Medical University of Lübeck, Germany

• Why and how to model a robust cost-effectiveness analysis in ART
  by S. Daya (Canada)

• Prevention of twin pregnancies after IVF/ICSI based on strict embryo criteria: final results of a prospective randomised clinical trial
  by J. Gerris (Belgium)

• A cost effectiveness analysis of Gonal-F® compared to urinary FSH in ART: results from the UK
  by W. Ledger (UK)

• Ovarian tissue cryopreservation and autograft
  by Aubard Y, Piver P and Driancourt MA

• Vertical transmission of hepatitis C virus
  by A.R. Zanetti
  Milan, Italy

Tuesday, June 27

• Axis orientation in embryonic development
  by Gardner R.L.

• Controlled ovarian stimulation during assisted reproduction techniques: a randomised, prospective, assessor-blind multicentre study comparing the efficacy and safety of recombinant FSH (Gonal-F®) with highly purified urinary FSH (Metrodin HP®)
  by Schats R. (The Netherlands)

• The effect of luteinising hormone administered during the late follicular phase in norm-ovulatory women undergoing in-vitro fertilisation
  by B.C. Tarlatzis (Greece)

• Minimal ovarian stimulation
  by F. Olivennes (France)

• Induction of final follicular maturation and early luteinisation in women undergoing ovulation induction for assisted reproduction: recombinant human gonadotrophin (Ovidrel®) versus urinary hCG (Profasi®)
  by J. Mills (Switzerland)

• Recombinant versus highly purified urinary FSH to induce ovulation induction and pregnancies in women over 35 years in an IVF/ICSI programme
  by M. Germond (Switzerland)

• Bring your kids!

• Assisted reproductive technology in Europe. 1997 results generated from European registers by ESHRE
  by Drs Karl Nygren (Stockholm, Sweden) and Anders Nyboe Andersen (Copenhagen, Denmark)

• A randomised controlled trial of IVF and ICSI in non-male factor infertility
  by Bhattacharya S et al.

• Luteal phase support using either progesterone gel (Crinone 8%®) or progesterone suppositories (Utrogest®): results of a prospective randomised study
  by Schwartz P et al.

• Recombinant human FSH (Gonal-F®) and leuprolide acetate (LA, Lupron®) administered in single or separate injections in women undergoing IVF: preliminary results
  by Silverberg KM et al.

• Oestradiol threshold therapy using the GnRH antagonist cetrorelix in women with endometriosis
  by Küpker W et al.

• Cetrotide®: Simplifying clinical practice
  by T. Hillensjö (Sweden)

• World-wide experience with Cetrotide® in the multiple dosing regimen
  by Diedrich K (Germany)

Wednesday, June 28

• The efficacy and safety of recombinant- versus urinary-human recombinant chorionic gonadotrophin in ovulation induction: results of a double-blind clinical study
  Warne D et al. (France)

• Psychological anxiety influences uterine contractility at the time of embryo transfer
  Fanchin et al. (France)

• Unexplained subfertility: to treat or not to treat?
  E.R. Te Velde (The Netherlands)

• Minimising the number of pre-ovulatory follicles in WHO group II anovulatory women over-responding to FSH with recombinant human luteinising hormone
  E. Loumaye (Switzerland)

• Axis orientation in embryonic development
  Gardner Richard (Belgium)

• The efficacy and safety of recombinant human luteinising hormone for minimising the number of pre-ovulatory follicles in WHO group I anovulatory women treated with rhFSH
  M. Arguinzoniz (Switzerland)

• Vaginal administration maximizes delivery of progesterone to the uterus through a local vagina-to-uterus functional 'portal' system
  Cicinelli E et al.

• Late breaking research session
  Embryo implantation and cancer metastasis: two faces of the same coin

---

D I S C L A I M E R

Feel free to send your questions or comments to:
thian@benecke.nl.

Subscribe / Unsubscribe

Visit our website for easy subscription/unsubscription,
or do the following:

To subscribe, send an email to
fnhigh-request@infopress.nl
Leave the subject empty, and type in the body:
SUBSCRIBE fnhigh followed by your_email_address
(e.g. SUBSCRIBE fnhigh thian@benecke.nl)
Do not add any other text.

To unsubscribe, send an email to
fnhigh-request@infopress.nl
Leave the subject empty, and type in the body:
UNSUBSCRIBE fnhigh followed by your_email_address
(e.g. UNSUBSCRIBE fnhigh thian@benecke.nl)
Do not add any other text.